cmd-003
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT01948180)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Epstein-Barr nuclear antigen 1Immunity, passive
Epstein-Barr T cells immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cmd-003
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02763254 | Phase 2 | Nov 1, 2016 | Kuur Therapeutics |
| NCT01948180 | Phase 2 | Sep 1, 2014 | Baylor University, Kuur Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kuur Therapeutics | For profit | 2 | 2 | 1 | 2014 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2014 |
2 organizations
Page 1 / 1